

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4339970

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CHENGBIN WU	07/20/2015
RECEIVING PARTY DATA	
Name:	EPIMAB BIOTHERAPEUTICS INC.
Street Address:	C/O 1335 PU CHI ROAD
Internal Address:	#56
City:	SHANGHAI
State/Country:	CHINA
Postal Code:	201112
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15146540
CORRESPONDENCE DATA	
Fax Number:	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	mteague@cooley.com
Correspondent Name:	MEGHANN K. TEAGUE
Address Line 1:	1299 PENNSYLVANIA AVENUE, NW
Address Line 2:	SUITE 700
Address Line 4:	WASHINGTON, D.C. 20004
ATTORNEY DOCKET NUMBER:	EPBI-001/02US 321091-2007
NAME OF SUBMITTER:	MEGHANN TEAGUE
SIGNATURE:	/Meghann Teague/
DATE SIGNED:	03/28/2017
Total Attachments: 4	
source=EPBI00102US_Parent_Assignment_#page1.tif	
source=EPBI00102US_Parent_Assignment_#page2.tif	
source=EPBI00102US_Parent_Assignment_#page3.tif	
source=EPBI00102US_Parent_Assignment_#page4.tif	

ASSIGNMENT

Chengbin WU, residing at #56, 1335 Pu Chi Road, Shanghai 201112, China; (referred to as "Assignor") has made an invention(s) (the "Invention(s)") set forth in an application for a patent, entitled FABS-IN-TANDEM IMMUNOGLOBULIN AND USES THEREOF, and which is a:

- (1) provisional application
 (a) to be filed herewith; or
 (b) bearing Application No. , and filed on ;
- (2) non-provisional application
 (a) to be filed herewith; or
 (b) bearing Application No. 14/732,088, and filed on June 5, 2015; or
- (3) PCT application
 (a) bearing Application No. PCT/US2014/072336, and filed on December 24, 2014.

WHEREAS, EPIMAB BIOTHERAPEUTICS INC., a Cayman Islands company having its principal place of business at c/o 1335 Pu Chi Road, #56, Shanghai, China 201112 (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention; the application for patent identified in paragraph (1), (2) and/or (3); the right to file applications for patent of the United States or other countries on the Invention; any application for patent of the United States or other countries claiming priority to this application; any provisional or other right to recover damages, including royalties, for prior infringements of these applications; and any patent of the United States or other countries that may be granted therefor or thereon.

WHEREAS, the Assignor, Assignee, and **EPIMAB BIOTHERAPEUTICS** (平湖益普生物制药技术有限公司) have entered into the Agreement and Release on July 5th, 2015 (the "Agreement");

NOW, THEREFORE, in connection with the Agreement, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application for patent identified in paragraph (1) (2) and/or (3);

(c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property and under the Patent Cooperation Treaty;

(d) any application(s) for patent of the United States or other countries claiming the Invention(s);

(e) any application(s) for patent of the United States or other countries claiming priority to the application for patent identified in paragraph (1), (2) and/or (3) or any application(s) for patent claiming the Invention(s), including any division(s), continuation(s), and continuation(s)-in-part; and

(f) any provisional or other right to recover damages, including royalties, for prior infringements of any application for patent identified in the preceding paragraphs (b)-(e); and

(g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b) – (e), including any reissue(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said applications, and said patents, including interference proceedings, without charge to the Assignor, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

July 20, 2015

July 20, 2015


Date: _____

Chengbin Wu

By: _____

Chengbin WU

Witnessed By:



Printed Name: Zhi Jin

Date:

July 20, 2015

7/20/2015

Date: July 20, 2015 By: Beifen Fei 费蓓芬
Name: Beifen Fei (费蓓芬)
Title: Director
Company: EPIMAB BIOTHERAPEUTICS
(平湖益普生物制药技术有限公司)

Witnessed By: Zhiming Jin
Printed Name: Zhiming Jin
Date: 7/20/2015